323 related articles for article (PubMed ID: 31258013)
1. Identification and validation of microRNAs that synergize with miR-34a - a basis for combinatorial microRNA therapeutics.
Orellana EA; Li C; Lisevick A; Kasinski AL
Cell Cycle; 2019 Aug; 18(15):1798-1811. PubMed ID: 31258013
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation.
Stahlhut C; Slack FJ
Cell Cycle; 2015; 14(13):2171-80. PubMed ID: 25714397
[TBL] [Abstract][Full Text] [Related]
3. The RNA-binding protein SART3 promotes miR-34a biogenesis and G
Sherman EJ; Mitchell DC; Garner AL
J Biol Chem; 2019 Nov; 294(46):17188-17196. PubMed ID: 31619517
[TBL] [Abstract][Full Text] [Related]
4. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
[TBL] [Abstract][Full Text] [Related]
5. The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.
Adams BD; Parsons C; Slack FJ
Expert Opin Ther Targets; 2016 Jun; 20(6):737-53. PubMed ID: 26652031
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-34a inhibits the proliferation and promotes the apoptosis of non-small cell lung cancer H1299 cell line by targeting TGFβR2.
Ma ZL; Hou PP; Li YL; Wang DT; Yuan TW; Wei JL; Zhao BT; Lou JT; Zhao XT; Jin Y; Jin YX
Tumour Biol; 2015 Apr; 36(4):2481-90. PubMed ID: 25501507
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251.
Luan S; Sun L; Huang F
Arch Med Res; 2010 Feb; 41(2):67-74. PubMed ID: 20470934
[TBL] [Abstract][Full Text] [Related]
8. The anti-tumor effects of CT-26 derived exosomes enriched by MicroRNA-34a on murine model of colorectal cancer.
Hosseini M; Baghaei K; Hajivalili M; Zali MR; Ebtekar M; Amani D
Life Sci; 2022 Feb; 290():120234. PubMed ID: 34953890
[TBL] [Abstract][Full Text] [Related]
9. Evaluating Synergistic Effects of miR-34a Mimics in Combination with Other Therapeutic Agents in Cultured Non-Small Cell Lung Cancer Cells.
Zhao J; Bader AG
Methods Mol Biol; 2017; 1517():115-126. PubMed ID: 27924478
[TBL] [Abstract][Full Text] [Related]
10. Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396800
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44.
Yu G; Yao W; Xiao W; Li H; Xu H; Lang B
J Exp Clin Cancer Res; 2014 Dec; 33(1):779. PubMed ID: 25551284
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of HMGB1 by miR-34a is sufficient to suppress proliferation, migration and invasion of human cervical and colorectal cancer cells.
Chandrasekaran KS; Sathyanarayanan A; Karunagaran D
Tumour Biol; 2016 Oct; 37(10):13155-13166. PubMed ID: 27456356
[TBL] [Abstract][Full Text] [Related]
13. Abberent expression of oncogenic and tumor-suppressive microRNAs and their target genes in human adenocarcinoma alveolar basal epithelial cells.
Tafsiri E; Darbouy M; Shadmehr MB; Cho WC; Karimipoor M
J Cancer Res Ther; 2016; 12(1):395-400. PubMed ID: 27072269
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of miR-34a contributes to the proliferation and migration of laryngeal carcinoma cells by targeting cyclin D1.
Ye J; Li L; Feng P; Wan J; Li J
Oncol Rep; 2016 Jul; 36(1):390-8. PubMed ID: 27220728
[TBL] [Abstract][Full Text] [Related]
15. Small RNA combination therapy for lung cancer.
Xue W; Dahlman JE; Tammela T; Khan OF; Sood S; Dave A; Cai W; Chirino LM; Yang GR; Bronson R; Crowley DG; Sahay G; Schroeder A; Langer R; Anderson DG; Jacks T
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):E3553-61. PubMed ID: 25114235
[TBL] [Abstract][Full Text] [Related]
16. Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor network.
Samuel N; Wilson G; Id Said B; Pan A; Deblois G; Fischer NW; Alexandrova R; Casallo G; Paton T; Lupien M; Gariepy J; Merico D; Hudson TJ; Malkin D
Oncotarget; 2016 Aug; 7(31):49611-49622. PubMed ID: 27391063
[TBL] [Abstract][Full Text] [Related]
17. Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
Zhao J; Guerrero A; Kelnar K; Peltier HJ; Bader AG
Lung Cancer; 2017 Jun; 108():96-102. PubMed ID: 28625657
[TBL] [Abstract][Full Text] [Related]
18. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
Kasinski AL; Slack FJ
Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
[TBL] [Abstract][Full Text] [Related]
19. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells.
Fujita Y; Kojima K; Hamada N; Ohhashi R; Akao Y; Nozawa Y; Deguchi T; Ito M
Biochem Biophys Res Commun; 2008 Dec; 377(1):114-9. PubMed ID: 18834855
[TBL] [Abstract][Full Text] [Related]
20. Verification of microRNA expression in human endometrial adenocarcinoma.
Jurcevic S; Klinga-Levan K; Olsson B; Ejeskär K
BMC Cancer; 2016 Apr; 16():261. PubMed ID: 27039384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
